This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Top Sectors of Last Week & Their Winning ETFs
by Sanghamitra Saha
These sectors topped last week and beat the broader market in a sweeping move.
Abbott Launches Antibody Test to Detect Coronavirus Infection
by Zacks Equity Research
Abbott (ABT) launches a lab-based serology blood test to detect the presence of antibodies post the coronavirus infection.
5 Best Leveraged ETF Areas of Last Week
by Sanghamitra Saha
If investors can identify the trending investing area amid all the coronavirus chaos, they can easily take a leveraged position on that and beat the broader market.
Stock Market News for Apr 17, 2020
by Zacks Equity Research
Benchmarks closed in the positive territory on Thursday led by gains in tech-related companies.
3 MedTech Stocks Likely to Have Braved Coronavirus Blow in Q1
by Sriparna Ghosal
Despite the widespread coronavirus crisis, there are a few MedTech companies which are expected to have gained in the first quarter.
Optimism Back in Wall Street? ETFs Areas to Win the Most
by Sanghamitra Saha
Wall Street is likely to stage a relief rally on hopes of reopening of American businesses, improving virus outlook and chances of treatment coming on stream.
Healthcare ETFs to Gain on Progress in COVID-19 Antibody Tests
by Sweta Jaiswal, FRM
Along with molecular testing, antibody testing is gaining immense prominence as economies are struggling to reopen.
How To Navigate The Choppy Markets
by Daniel Laboe
22 million filed for unemployment in the past month, the SBA fund ran dry, pandemic case count tops 2 million, and it will likely be months before the economy is able to safely open up. So, is the S&P 500's 28% recovery justified?
5.25M More Jobless Claims, Plus Starts & Permits, Philly Fed Down
by Mark Vickery
Initial and Continuing Jobless Claims, Housing Starts and Building Permits, and the Philly Fed join the latest batch of Q1 earnings reports this morning.
Abbott (ABT) Beats on Q1 Earnings, Suspends '20 Guidance
by Zacks Equity Research
Uncertainties about the duration and impact of the coronavirus pandemic on its overall business compel Abbott (ABT) to suspend its full-year guidance.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge
Abbott (ABT) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 18.18% and 8.38%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Buy Abbott (ABT) Stock Ahead of Earnings on Coronavirus Testing Push?
by Benjamin Rains
The FDA has approved two different Abbott coronavirus tests. So now the question for investors is should they consider buying ABT shares with the firm set to report its Q1 fiscal 2020 financial results on Thursday, April 16?
Solid Diagnostics to Aid Abbott (ABT) Q1 Earnings Amid Crisis?
by Zacks Equity Research
Though the magnitude of loss due to the virus outbreak in Abbott's (ABT) Core Laboratory business is still unclear, the company's point-of-care business is anticipated to generate profit.
Amazon (AMZN) to Boost Worker Safety With Testing Lab Facility
by Zacks Equity Research
Amazon (AMZN) to build coronavirus testing lab to ensure safety of its workers.
Will Low Product Revenues Impact Abbott (ABT) Q1 Earnings?
by Zacks Equity Research
Revenues of Abbott's (ABT) Diabetes Care business, which has been, otherwise on a strong growth trajectory, are likely to have declined in Q1 due to the coronavirus-related market turbulence.
Coronavirus Testing, Vaccines & Treatments: What You Should Know
by Neena Mishra
We discuss latest developments in tests, vaccines and therapies for COVID-19.
Earnings Preview: Abbott (ABT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
This $5 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies
What to Expect from Big Bank Earnings Amid the Coronavirus?
by Sheraz Mian
The S&P 500 index is now down -14% this year through Thursday, April 9, while the Major Banks industry is still down more than -37%. This underperformance is not surprising, given the group's exposure to a sharp economic downturn...
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $81.90, moving -1% from the previous trading session.
Luminex (LMNX) Receives EUA for Coronavirus Detection Test
by Zacks Equity Research
Luminex (LMNX) receives EUA for its ARIES SARS-CoV-2 Assay, which will be used to rapidly detect the virus causing COVID-19.
These Medical ETFs & Stocks Deserve a Salute on Health Day
by Sanghamitra Saha
The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.
Amazon (AMZN) in Talks With Test Makers to Screen Workers
by Zacks Equity Research
Amazon (AMZN) is in contact with Abbott Laboratories and Thermo Fisher Scientific to introduce coronavirus testing at its warehouses.
Healthcare Stocks & ETFs to Gain on Coronavirus Test Progress
by Sweta Jaiswal, FRM
It seems that testing for COVID-19 is the major key in controlling the outbreak and helps in making decisions like treatment protocols, resource allocation and drafting the right healthcare policies.